Stopping Membrane-Enveloped Viruses with Nanotechnology Strategies: Toward Antiviral Drug Development and Pandemic Preparedness

Yoon, Bo Kyeong; Jeon, Won-Yong; Sut, Tun Naw; Cho, Nam‐Joon; Jackman, Joshua A.

doi:10.1021/acsnano.0c07489

Cited by 51 publications

(48 citation statements)

References 199 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This ability to evade the host immune response could present an important factor in viral infection outbreaks. Even though the non-enveloped viruses are more likely to establish human-to-human transmission 14 , the majority of the recent years viral epidemics such as Ebola, measles, Zika, avian influenzas, SARS, MERS, and the ongoing COVID-19, have been caused by enveloped viruses 15,16 . Although the lipid bilayer in enveloped viruses can offer additional protection to the virus, it can also be detrimental to their survival outside of the host cell as the lipid bilayer can degrade upon harsh physical or chemical conditions.…”

mentioning

confidence: 99%

Antiviral surfaces and coatings and their mechanisms of action

et al. 2021

View full text Add to dashboard Cite

Viral infections are a serious health challenge, and the COVID-19 pandemic has increased the demand for antiviral measures and treatments for clean surfaces, especially in public places. Here, we review a range of natural and synthetic surface materials and coatings with antiviral properties, including metals, polymers and biopolymers, graphene and antimicrobial peptides, and their underpinning antiviral mechanisms. We also discuss the physico-chemical properties of surfaces which influence virus attachment and persistence on surfaces. Finally, an overview is given of the current practices and applications of antiviral and virucidal materials and coatings in consumer products, personal protective equipment, healthcare and public settings.

show abstract

mentioning

confidence: 99%

Antiviral surfaces and coatings and their mechanisms of action

et al. 2021

View full text Add to dashboard Cite

show abstract

“…3 Egg PC = egg phosphatidylcholine; 4 DOPC = 1,2-dioleoyl-sn-glycero-3-phosphocholine; 5 PCL-PEG-PCL = poly(ε-caprolactone)-poly(ethylene glycol)-poly(ε-caprolactone); 6 LNC was composed of poly-oxyl 15 hydroxy-stearate surfactant, lecithin, caprylic/capric acid triglycerides, and fatty acid or monoglyceride as a co-surfactant. 7 NLC was composed of a mixture of glyceryl palmitostearate, medium-chain triglycerides, Tween-60 surfactant, and DHA.…”

Section: Dha H Pylori (-)mentioning

confidence: 99%

“…NLC oily phase comprised Tween 80, oleic acid, doxorubicin, triethanolamine, glyceryl di-behenate, and DHA; aqueous phase comprised EDTA and water 6. Both NEs and NLCs had poloxamer 188 as the aqueous phase within the nanoparticle design 7. SLN oily phase comprised Tween 80, butylated hydroxytoluene, doxorubicin, triethanolamine or stearyl-amine, and DHA; aqueous phase comprised EDTA and water 8.…”

mentioning

confidence: 99%

Lipid Nanoparticle Technology for Delivering Biologically Active Fatty Acids and Monoglycerides

Tan

Yoon

Cho

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

There is enormous interest in utilizing biologically active fatty acids and monoglycerides to treat phospholipid membrane-related medical diseases, especially with the global health importance of membrane-enveloped viruses and bacteria. However, it is difficult to practically deliver lipophilic fatty acids and monoglycerides for therapeutic applications, which has led to the emergence of lipid nanoparticle platforms that support molecular encapsulation and functional presentation. Herein, we introduce various classes of lipid nanoparticle technology and critically examine the latest progress in utilizing lipid nanoparticles to deliver fatty acids and monoglycerides in order to treat medical diseases related to infectious pathogens, cancer, and inflammation. Particular emphasis is placed on understanding how nanoparticle structure is related to biological function in terms of mechanism, potency, selectivity, and targeting. We also discuss translational opportunities and regulatory needs for utilizing lipid nanoparticles to deliver fatty acids and monoglycerides, including unmet clinical opportunities.

show abstract

“…When looking at the scientific questions involved, one can justifiably argue that control of SARS-CoV-2 is, at least to a certain extent, a colloidal question [ 2 ]. In this context, the topic of how nanotechnology can be employed for stopping enveloped viruses has been reviewed recently [ 3 ], and the same applies to the antiviral properties of polymers [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Surfactants – Compounds for inactivation of SARS-CoV-2 and other enveloped viruses

Simon

Veit

Osterrieder

et al. 2021

Current Opinion in Colloid & Interface Science

View full text Add to dashboard Cite

We provide here a general view on the interactions of surfactants with viruses, with a particular emphasis on how such interactions can be controlled and employed, for inhibiting the infectivity of enveloped viruses, including coronaviruses. The aim is to provide to interested scientists from different fields, including chemistry, physics, biochemistry, and medicine, an overview over the basic properties of surfactants and (corona)viruses, which are relevant to understanding the interactions between the two. Various types of interactions between surfactant and virus are important, and they act on different components of a virus such as the lipid envelope, membrane (envelope) proteins and nucleo-capsid proteins. Accordingly, this cannot be a detailed account of all relevant aspects, but instead a summary that bridges between the different disciplines. We describe concepts and cover a selection of the relevant literature as an incentive for diving deeper into the relevant material. Our focus is on more recent developments around the COVID-19 pandemic caused by SARS-CoV-2, applications of surfactants against the virus, and on the potential future use of surfactants for pandemic relief. However, we also cover the most important aspects of the historical development of using surfactants in combatting virus infections. We conclude that surfactants are already playing very important roles in various directions of defence against viruses, either directly, as in disinfection, or as carrier components of drug delivery systems for prophylaxis or treatment. By designing tailor-made surfactants and, consequently, advanced formulations, one can expect a more and more effective use of surfactants, either directly as antiviral compounds or as part of more complex formulations.

show abstract

Stopping Membrane-Enveloped Viruses with Nanotechnology Strategies: Toward Antiviral Drug Development and Pandemic Preparedness

Cited by 51 publications

References 199 publications

Antiviral surfaces and coatings and their mechanisms of action

Antiviral surfaces and coatings and their mechanisms of action

Lipid Nanoparticle Technology for Delivering Biologically Active Fatty Acids and Monoglycerides

Surfactants – Compounds for inactivation of SARS-CoV-2 and other enveloped viruses

Contact Info

Product

Resources

About